Hanmi Pharmaceutical has completed its acquisition of North American oncology-focused biotech company Aptose Biosciences.

The acquisition fulfills contractual obligations under an agreement signed by the company's previous management in 2025. Hanmi’s current board plans to evaluate the long-term value of Aptose’s assets before determining future development plans.

According to industry sources on July 3, Hanmi finalized its acquisition of a 100% stake in Aptose, the company to which it licensed the investigational cancer drug tuspetinib in 2021. As a result, the rights to tuspetinib have effectively reverted to Hanmi Pharmaceutical.

The total cost of the acquisition was approximately <strong>$46.7 million</strong>, including roughly <strong>$37.9 million</strong> in loans previously extended to Aptose.

A Hanmi Pharmaceutical official said the acquisition was successfully completed in accordance with the original agreement, adding that additional financial impacts could arise depending on the outcome of the post-acquisition asset valuation.

The company said it will disclose the results of the asset evaluation and its future development plans through its regular regulatory filings.

Hanmi Pharmaceutical has completed its acquisition of North American oncology-focused biot …

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences